Joseph Oliveto Sells 36,500 Shares of Milestone Pharmaceuticals (NASDAQ:MIST) Stock

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) CEO Joseph Oliveto sold 36,500 shares of the company’s stock in a transaction that occurred on Thursday, April 16th. The shares were sold at an average price of $2.26, for a total transaction of $82,490.00. Following the completion of the transaction, the chief executive officer owned 446,244 shares of the company’s stock, valued at approximately $1,008,511.44. This trade represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Joseph Oliveto also recently made the following trade(s):

• On Monday, January 26th, Joseph Oliveto sold 34,523 shares of Milestone Pharmaceuticals stock. The shares were sold at an average price of $1.93, for a total transaction of $66,629.39.

Milestone Pharmaceuticals Trading Down 5.9%

Shares of NASDAQ MIST opened at $1.92 on Wednesday. The company has a debt-to-equity ratio of 1.37, a quick ratio of 7.96 and a current ratio of 8.01. Milestone Pharmaceuticals Inc. has a 52-week low of $0.98 and a 52-week high of $3.06. The firm has a 50 day moving average price of $1.66 and a two-hundred day moving average price of $1.94. The stock has a market cap of $225.93 million, a P/E ratio of -2.43 and a beta of 0.69.

Milestone Pharmaceuticals (NASDAQ:MIST) last announced its quarterly earnings results on Friday, March 20th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $37.52 million. As a group, equities analysts forecast that Milestone Pharmaceuticals Inc. will post -0.64 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Zacks Research lowered shares of Milestone Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 29th. Raymond James Financial assumed coverage on shares of Milestone Pharmaceuticals in a research note on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Milestone Pharmaceuticals in a research note on Tuesday, January 6th. Finally, Wall Street Zen lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.50.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Large investors have recently bought and sold shares of the stock. Strategic Family Wealth Counselors L.L.C. acquired a new stake in Milestone Pharmaceuticals in the fourth quarter worth $25,000. Sapient Capital LLC acquired a new stake in Milestone Pharmaceuticals in the third quarter worth $25,000. Eaton Financial Holdings Company LLC acquired a new stake in Milestone Pharmaceuticals in the fourth quarter worth $26,000. Bank of America Corp DE grew its holdings in Milestone Pharmaceuticals by 200,550.0% in the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after purchasing an additional 16,044 shares during the period. Finally, Stephenson & Company Inc. acquired a new stake in Milestone Pharmaceuticals in the third quarter worth $40,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.